Other substances

Captopril

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

Supporting references

Contradictory references

AI-suggested references

Clinical trials

Supporting references

Link	Tested on	Impact factor	Notes	Publication date
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing Small molecule	in silico	42.78		Apr/30/2020

AI-suggested references

Link	Publication date
Potential inhibitors of angiotensin converting enzyme 2 receptor of COVID-19 by Corchorus olitorius Linn using docking, molecular dynamics, conceptual DFT investigation and pharmacophore mapping.	Mar/11/2021
Molecular modeling of the interaction of ligands with ACE2-SARS-CoV-2 spike protein complex	Oct/07/2021
ACE2 as a potential therapeutic target for pandemic COVID-19	Nov/01/2020
Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial Cells	Nov/19/2021
FDA-approved thiol-reacting drugs that potentially bind into the SARS-CoV-2 main protease, essential for viral replication	Dec/17/2020
In silico study the inhibition of angiotensin converting enzyme 2 receptor of COVID-19 by Ammoides verticillata components harvested from Western Algeria	Apr/22/2020
Characterization of ACE Inhibitors and AT1R Antagonists with Regard to Their Effect on ACE2 Expression and Infection with SARS-CoV-2 Using a Caco-2 Cell Model	Aug/10/2021
Vascular Effects of Low-Dose ACE2 Inhibitor MLN-4760:Benefit or Detriment in Essential Hypertension?	Sep/26/2021
Captopril alleviates lung inflammation in SARS-CoV-2-infected hypertensive mice	Aug/24/2021

Clinical trials

ID	Title	Status	Phase	Start date	Completion date
NCT04578236	Efficacy of Aerosol Combination Therapy of 13 Cis Retinoic Acid and Captopril for Treating Covid-19 Patients Via Indirect Inhibition of Transmembrane Protease, Serine 2 (TMPRSS2)	Not yet recruiting	Phase 2	Nov/01/2020	Jan/01/2021
Alternative id - SARS Interventions - Combination Product: Aerosolized 13 cis retinoic acid plus Inhalation administration by nebulization captopril 25mg\|Drug: Drug: Standard treatment Standard treatment Study type - Interventional Study results - No Results Available Locations - Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 360 Age - 18 Years to 80 Years (Adult, Older Adult) Outcome measures - lung injury score\|Transe membrane protease ,serine II (TMPRSS2) changes over time\|Testosterone levels changes over time\|Dihydrotestosterone(DHT) levels changes over time\|Cholesterol levels changes over time\|Angiotensin 1-7 (Ang 1-7) changes over time\|Angiotensin 1-5 (Ang 1-5) changes over time\|Renin changes over time\|Aldosterone changes over time\|Angiotensin-converting enzyme (ACE) changes over time\|Time to first negative SARS-CoV-2 PCR in NP swap\|All cause mortality rate\|Ventilation free days\|ICU free days
NCT04355429	Efficacy of Captopril in Covid-19 Patients With Severe Acute Respiratory Syndrome (SARS) CoV-2 Pneumonia (CAPTOCOVID)	Not yet recruiting	Phase 2	May/05/2020	Aug/01/2020
Alternative id - APHP200410 Interventions - Drug: captopril 25mg Study type - Interventional Study results - No Results Available Locations - CH Victor Dupuy- Argenteuil, Argenteuil, France\|Hôpital Avicenne,, Bobigny, France\|Hôpital Avicenne, Bobigny, France\|Hôpital Avicenne, Bobigny, France\|Hôpital Antoine Béclère, Clamart, France\|CH de Compiègne-Noyon, Compiègne, France\|Groupe hospitalier Sud Ile de France, Melun, France\|Hôpital de la Pitié- Salpêtrière, Paris, France\|Hôpital Tenon, Paris, France\|CHRU de Tours, Hôpital Bretonneau, Tours, France\|Hôpital de Tours, Tours, France Study designs - Allocation: Randomized\|Intervention Model: Parallel Assignment\|Masking: None (Open Label)\|Primary Purpose: Treatment Enrollment - 230 Age - 18 Years and older (Adult, Older Adult) Outcome measures - Efficacy of captopril nebulization addition to standard of care compared to standard of care.